Clinical Trial: Vitamin E Versus Silymarin in Non Diabetic MASLD Patients

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07863648) titled 'Vitamin E Versus Silymarin in Non Diabetic MASLD Patients' on Oct. 02.

Brief Summary: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. Silymarin has clinical evidence supports its use as an adjunctive hepatoprotective agent due to...